Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 18 04:00PM ET
0.8370
Dollar change
-0.0219
Percentage change
-2.55
%
Index- P/E- EPS (ttm)-0.15 Insider Own0.44% Shs Outstand408.82M Perf Week-6.56%
Market Cap342.18M Forward P/E- EPS next Y-0.13 Insider Trans-1.08% Shs Float407.04M Perf Month-31.39%
Income-59.26M PEG- EPS next Q-0.03 Inst Own23.55% Short Float4.17% Perf Quarter1.07%
Sales308.22M P/S1.11 EPS this Y6.67% Inst Trans-7.25% Short Ratio6.69 Perf Half Y-17.13%
Book/sh1.35 P/B0.62 EPS next Y9.52% ROA-6.90% Short Interest16.99M Perf Year-48.65%
Cash/sh0.79 P/C1.07 EPS next 5Y38.90% ROE-10.33% 52W Range0.65 - 1.66 Perf YTD-3.79%
Dividend Est.- P/FCF- EPS past 5Y17.93% ROI-10.57% 52W High-49.58% Beta2.02
Dividend TTM- Quick Ratio1.80 Sales past 5Y14.60% Gross Margin53.00% 52W Low28.57% ATR (14)0.07
Dividend Ex-Date- Current Ratio2.80 EPS Y/Y TTM44.82% Oper. Margin-18.41% RSI (14)33.59 Volatility6.80% 7.25%
Employees275 Debt/Eq0.02 Sales Y/Y TTM-16.19% Profit Margin-19.23% Recom3.00 Target Price1.08
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q-780.95% Payout- Rel Volume0.43 Prev Close0.86
Sales Surprise12.76% EPS Surprise62.83% Sales Q/Q-17.11% EarningsFeb 29 BMO Avg Volume2.54M Price0.84
SMA20-19.96% SMA50-24.60% SMA200-16.95% Trades Volume1,088,076 Change-2.55%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Underweight
Oct-25-23Downgrade Jefferies Buy → Hold $3 → $1
Jan-06-23Upgrade Jefferies Hold → Buy $1.30 → $3
May-06-22Downgrade JP Morgan Neutral → Underweight
May-05-22Downgrade SVB Leerink Outperform → Mkt Perform $10 → $3
May-05-22Downgrade H.C. Wainwright Buy → Neutral $10 → $3
May-04-22Downgrade Northland Capital Outperform → Market Perform
May-12-21Downgrade Goldman Neutral → Sell $6 → $5
Sep-29-20Resumed JP Morgan Neutral
Aug-26-20Initiated Piper Sandler Overweight $21
Mar-01-24 09:30AM
08:39AM
Feb-29-24 03:30PM
07:37AM
07:34AM
07:00AM Loading…
07:00AM
Feb-15-24 08:00AM
Jan-22-24 07:30AM
Jan-12-24 09:40AM
Jan-11-24 09:34AM
Jan-10-24 07:02PM
07:00AM
Dec-26-23 07:13PM
Dec-11-23 08:00AM
Dec-05-23 12:00PM
09:00AM Loading…
Nov-12-23 09:00AM
Nov-02-23 10:58AM
Nov-01-23 12:30PM
12:03PM
09:30AM
09:25AM
07:30AM
07:00AM
Oct-31-23 12:00PM
Oct-26-23 08:00AM
Oct-23-23 10:08AM
Oct-19-23 08:00AM
Sep-12-23 08:00AM
Aug-24-23 09:29AM
Aug-19-23 11:22AM
04:05PM Loading…
Aug-09-23 04:05PM
Aug-08-23 07:00AM
Aug-07-23 07:00AM
Aug-03-23 11:22AM
Aug-02-23 07:33AM
07:11AM
Jul-31-23 08:00AM
Jul-28-23 02:56PM
Jul-26-23 08:00AM
Jul-25-23 04:05PM
Jul-20-23 08:00AM
Jul-19-23 12:58PM
11:19AM
Jul-18-23 04:16PM
04:15PM
Jul-05-23 11:43AM
Jun-21-23 09:00AM
Jun-08-23 11:07AM
Jun-01-23 04:30PM
06:00AM
May-23-23 09:50AM
May-12-23 11:00AM
May-03-23 02:00PM
01:47PM
07:41AM
07:00AM
May-02-23 01:32PM
Apr-19-23 08:00AM
Apr-17-23 07:00AM
Apr-13-23 10:18AM
Apr-12-23 09:18AM
Apr-04-23 03:53PM
08:00AM
Mar-16-23 08:00AM
Mar-06-23 04:05PM
09:37AM
08:00AM
Mar-05-23 10:21AM
Mar-03-23 11:09AM
Mar-02-23 01:23PM
11:44AM
05:55AM
Mar-01-23 11:02AM
11:00AM
07:00AM
Feb-28-23 11:11AM
10:39AM
10:38AM
08:00AM
Feb-27-23 04:29PM
08:00AM
07:15AM
Feb-24-23 11:52AM
Feb-22-23 04:50PM
08:00AM
Feb-21-23 08:30AM
08:00AM
Feb-20-23 01:00PM
Feb-17-23 09:03AM
07:30AM
Feb-16-23 04:05PM
12:34PM
09:44AM
Feb-15-23 04:29PM
Feb-14-23 05:09PM
09:55AM
Feb-13-23 07:47PM
09:40AM
08:00AM
08:00AM
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holt PatrickPresident and CEOJan 22 '24Buy1.0914,42615,724314,426Jan 24 04:31 PM
Ketchum Steven BChief Scientific OfficerDec 12 '23Sale0.7934,13126,963566,100Dec 14 06:35 PM
Holt PatrickPresident and CEOAug 16 '23Buy1.04300,000312,315300,000Aug 16 07:51 PM